Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 204)
Posted On: 07/25/2019 5:14:50 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Agreement Increases Reach of Ingested Cannabis Absorption Technology
- Cannabis users have historically preferred to inhale smoke from the burned plant in order to achieve rapid-onset absorption of its properties, but Lexaria Bioscience is making it possible to achieve similar results through oral ingestion
- Lexaria’s revolutionary DehydraTECH technology allows cannabis users to eliminate the unhealthy effects of smoking from their routines, and the product is being tested with nicotine as well
- Cannabis-infused edibles sales are expected to climb from about $1 billion currently to about $4.1 billion by 2022
Consumable bioactive product innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will expand the reach of its revolutionary DehydraTECH technology across the United States courtesy of a definitive five-year agreement that allows B2B hemp substance manufacturing firm Universal Hemp LLC to include it in many cannabidiol (CBD)-based food ingredients.
Lexaria’s DehydraTECH is an ingested drug delivery platform patented to work with all psychoactive and non-psychoactive cannabinoids (http://nnw.fm/GuZ96), making them bioavailable through absorption at a rate comparable to the rapid-onset effect of inhaled cannabis without the detrimental health effects that arise from smoking. The Lexaria technology accomplishes this by speeding the rate of absorption for chemicals in edibles – an otherwise slow means of making substances bioavailable through the bloodstream.
DehydraTECH also allows the substances to be ingested without the need for the unhealthy sweeteners that are commonly used in cannabis-infused products to mask bitter tastes, according to the company.
The Universal Hemp agreement packages DehydraTECH with food ingredients to be produced for the nutraceutical and consumer packaged goods industries. In addition to the United States, outlets in Canada will be included once that country’s regulations allow edible cannabis products.
“In terms of bioavailability, shelf stability and taste this is the best performing technology in the market, hands down. Our corporate customers cannot wait to put our water-soluble solution into their products!” Universal Hemp CEO and Founder Chad Kahunahana stated in a news release about the agreement (http://nnw.fm/7ioNc).
Chris Bunka, CEO of Lexaria Bioscience, noted that the agreement’s new inroads to the hemp industry will not only deliver rapid product uptake, but also allow the company to deliver precision dosing and maximum product strength. Cannabis industry publication Green Entrepreneur reported that cannabis-infused edibles sales reached over $1 billion in 2018 and are expected to amount to about $4.1 billion by 2022 (http://nnw.fm/0spR0), showing an exponential level of growth.
In addition, Lexaria also recently announced its entry into a CBD beverage license agreement with Nic’s Beverages LLC for use in CBD-based beverages to be produced and sold throughout the United States. Nic’s Beverages will initially produce ready-to-drink (RTD) cold brew coffees enhanced with CBD from multi-spectrum hemp oil (http://nnw.fm/OG4lI).
Lexaria is the only company in the world to have a patent issued for the oral delivery of all cannabinoids. DehydraTECH has received 11 patents in the United States and Australia, and it has about 60 additional patents pending in more than 40 countries worldwide. The DehydraTECH platform has also been used in research on nicotine absorption (http://nnw.fm/FaU7U).
The company’s informative July 11 investor conference video on Virtual Investor Conferences’ series site is now accessible online, as noted in a news release (http://nnw.fm/GtU2m).
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Cannabis users have historically preferred to inhale smoke from the burned plant in order to achieve rapid-onset absorption of its properties, but Lexaria Bioscience is making it possible to achieve similar results through oral ingestion
- Lexaria’s revolutionary DehydraTECH technology allows cannabis users to eliminate the unhealthy effects of smoking from their routines, and the product is being tested with nicotine as well
- Cannabis-infused edibles sales are expected to climb from about $1 billion currently to about $4.1 billion by 2022
Consumable bioactive product innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will expand the reach of its revolutionary DehydraTECH technology across the United States courtesy of a definitive five-year agreement that allows B2B hemp substance manufacturing firm Universal Hemp LLC to include it in many cannabidiol (CBD)-based food ingredients.
Lexaria’s DehydraTECH is an ingested drug delivery platform patented to work with all psychoactive and non-psychoactive cannabinoids (http://nnw.fm/GuZ96), making them bioavailable through absorption at a rate comparable to the rapid-onset effect of inhaled cannabis without the detrimental health effects that arise from smoking. The Lexaria technology accomplishes this by speeding the rate of absorption for chemicals in edibles – an otherwise slow means of making substances bioavailable through the bloodstream.
DehydraTECH also allows the substances to be ingested without the need for the unhealthy sweeteners that are commonly used in cannabis-infused products to mask bitter tastes, according to the company.
The Universal Hemp agreement packages DehydraTECH with food ingredients to be produced for the nutraceutical and consumer packaged goods industries. In addition to the United States, outlets in Canada will be included once that country’s regulations allow edible cannabis products.
“In terms of bioavailability, shelf stability and taste this is the best performing technology in the market, hands down. Our corporate customers cannot wait to put our water-soluble solution into their products!” Universal Hemp CEO and Founder Chad Kahunahana stated in a news release about the agreement (http://nnw.fm/7ioNc).
Chris Bunka, CEO of Lexaria Bioscience, noted that the agreement’s new inroads to the hemp industry will not only deliver rapid product uptake, but also allow the company to deliver precision dosing and maximum product strength. Cannabis industry publication Green Entrepreneur reported that cannabis-infused edibles sales reached over $1 billion in 2018 and are expected to amount to about $4.1 billion by 2022 (http://nnw.fm/0spR0), showing an exponential level of growth.
In addition, Lexaria also recently announced its entry into a CBD beverage license agreement with Nic’s Beverages LLC for use in CBD-based beverages to be produced and sold throughout the United States. Nic’s Beverages will initially produce ready-to-drink (RTD) cold brew coffees enhanced with CBD from multi-spectrum hemp oil (http://nnw.fm/OG4lI).
Lexaria is the only company in the world to have a patent issued for the oral delivery of all cannabinoids. DehydraTECH has received 11 patents in the United States and Australia, and it has about 60 additional patents pending in more than 40 countries worldwide. The DehydraTECH platform has also been used in research on nicotine absorption (http://nnw.fm/FaU7U).
The company’s informative July 11 investor conference video on Virtual Investor Conferences’ series site is now accessible online, as noted in a news release (http://nnw.fm/GtU2m).
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)